Falecalcitriol

Drugs of the Future

Volumn 22, Issue 5, 1997, Pages 473-480

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FALECALCITRIOL; HEXAFLUOROCALCITRIOL; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONFORMATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPARATHYROIDISM; LD 50; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; REPRODUCTIVE TOXICITY; REVIEW; STRUCTURE ACTIVITY RELATION; TERATOGENICITY; VITAMIN D METABOLISM;

EID: 1842378573     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.05.408603     Document Type: Review

References (50)

1. 3. J Chem Soc Chem Commun 1980, 459-60.
2. DeLuca, H.F., Tanaka, Y., Ikekawa, N., Kobayashi, Y. (Wisconsin Alumni Res. Found.). 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing the same. JP 94025280, US 4358406.
3. 3. Chem Pharm Bull 1982, 30: 4297-303.
4. 3. Amer J Physiol 1983, 244: E159-63.
5. 3. In: Vitamin D. Molecular, Cellular and Clinical Endocrinology, A.W. Norman, K. Schaefer, H.-G. Grigoleit and D.v. Herrath (Eds.), Walter de Gruyter & Co, Berlin, New York, 1988, 141-2.
6. 3. Arch Biochem Biophys 1984, 229: 348-54.
7. Inaba, M., Okuno, S., Nishizawa, Y., Yukioka, K., Otani, S., Matsui-Yuasa, I., Morisawa, S., DeLuca, H.F., Morii, H. Biological activity of fluorinated vitamin D analogs at C-26 and C-27 on human promyelocytic leukemia cells, HL-60. Arch Biochem Biophys 1987, 258: 421-5.
8. 3 in the chick. Acta Endocrinol 1989, 121: 520-4.
9. 3 on human bone-derived cells. Endocrinology 1991, 128: 81-6.
10. Katsumata, T., Ishibashi, E., Tanaka, T., Nakatsuka, M. Biological activity of falecalcitriol. Clin Rep 1996, 30(11): 271-8.
11. Nakatsuka, K., Imanishi, Y., Morishima, Y. et al. Biological potency of a fluorinated vitamin D analogue in hypoparathyroidism. Bone Miner 1992, 16: 73-81.
12. Miyamoto, Y., Shinki, T., Ohyama, Y., Kasama, T., Iwasaki, H., Hosotani, R., Sato, T., Suda, T. Regulation of vitamin D-responsive gene expression by fluorinated analogs of calcitriol in rat osteoblastic ROB-C26 cells. J Biochem 1995, 118: 1068-76.
13. 3. Bone 1995, 16(1, Suppl.): Abst 128.
14. Tsushima, N., Katsumata, T., Ishibashi, E., Negoro, T., Nakatsuka, M. Therapeutic effects of falecalcitriol on secondary hyperparathyroidism and osteodystrophy in 5/6 nephrectomized rats. Clin Rep 1996, 30(11): 279-90.
15. 3 in bone resorption in organ culture. Int Conf Osteoporosis (Nov 5-7, Kobe) 1991, Abst 182.
16. Katsumata, T., Tsushima, N., Ishibashi, E., Nakatsuka, M. Antirachitic effect of falecalcitriol - On vitamin D-deficient rachitic rats and hypophosphatemic mice. Clin Rep 1996, 30(11): 291-8.
17. 3 receptor macromolecules in MC3T3-E1 cells: Affinity of hexafluoro analog of 1,25-dihydroxyvitamin D3, ST-630, for these forms. Res Commun Mol Pathol Pharmacol 1994, 85: 3-13.
18. Iizuka, H., Unakami, S., Yamaguchi, K., Hirata, M., Suzuki, S., Makita, Y., Yamazaki, R., Higuchi, S. General pharmacology of ST-630. Jpn Pharmacol Ther 1997, 25(2): 103-38.
19. Yamada, T., Inoue, T., Tarumoto, Y., Imai, S., Toyohara, S., Kawanishi, H. Reproductive and developmental toxicity studies of (+) - (5Z,7E) - 26,26,26,27,27,27 - hexafluoro - 9,10 - secocholesta-5,7,10(19)-triene-1α,3β,25-triol (ST-630) 1. Fertility study in rats. Pharmacometrics 1996, 52: 1-10.
20. Yamada, T., Inoue, T., Tarumoto, Y., Imai, S., Toyohara, S., Kawanishi, H. Reproductive and developmental toxicity studies of (+) - (5Z,7E) - 26,26,26,27,27,27 - hexafluoro - 9,10 - secocholesta-5,7,10(19)-triene-1α,3β,25-triol (ST-630) 2. Teratogenicity study in rats. Pharmacometrics 1996, 52: 11-25.
21. Yamada, T., Inoue, T., Tarumoto, Y., Imai, S., Toyohara, S., Kawanishi, H. Reproductive and developmental toxicity studies of (+) - (5Z,7E) - 26,26,26,27,27,27 - hexafluoro - 9,10 - secocholesta-5,7,10(19) -triene-1α,3β,25-triol (ST-630) 4. Prenatal and postnatal study in rats. Pharmacometrics 1996, 52: 37-48.
22. Yamada, T., Inoue, T., Tarumoto, Y., Imai, S., Toyohara, S., Kawanishi, H. Reproductive and developmental toxicity studies of (+) - (5Z,7E) - 26,26,26,27,27,27 - hexafluoro - 9,10 - secocholesta-5,7,10(19) -triene-1α,3β,25-triol (ST-630) 3. Teratogenicity study in rabbits. Pharmacometrics 1996, 52: 27-35.
23. Yamada, H., Nakayama, N., Sugiura, M., Kawanishi, M., Kimura, M., Ohshima, T., Tarumoto, Y., Hatayama, K., Nishimura, N., Ukon, Y. Toxicity studies of (+)-(5Z,7E)-26,26,26,27,27,27-hexafluoro - 9,10 - secocholesta - 5,7,10(19) - triene - 1α,3β,25 - triol (ST-630) (the 1st report) - Acute oral toxicity of ST-630 in mice, rats and dogs, and acute intravenous toxicity of the main metabolite, ST-232, in rats. Clin Rep 1996, 30(11): 11-23.
24. Yagi, K., Takenaka, C., Sakai, S., Kimura, M., Ohshima, T., Tarumoto, Y. Toxicity studies of (+)-(5Z,7E)-26,26,26,27,27,27-hexafluoro - 9,10 - secocholesta - 5,7,10(19) - triene - 1α,3β,25 -triol (ST-630) (the 2nd report) - Three-month oral repeated dose toxicity study in rats. Clin Rep 1996, 30(11): 25-54.
25. Nakamura, I., Sakagawa, T., Kawanishi, M., Ohno, R., Kimura, M., Tarumoto, Y. Toxicity studies of (+)-(5Z,7E)-26,26,26,27,27,27-hexafluoro - 9,10 - secocholesta - 5,7,10(19) - triene - 1α,3β,25 -triol (ST-630) (the 3rd report) - Three-month oral repeated dose toxicity study in beagle dogs. Clin Rep 1996, 30(11): 55-73.
26. Yagi, K., Shirane, R., Kimura, M., Ohshima, T., Tarumoto, Y., Imai, S., Kawanishi, H. Toxicity studies of (+)-(5Z,7E)-26,26,26,27, 27,27 - hexafluoro - 9,10 - secocholesta - 5,7,10(19) - triene -1α,3β,25-triol (ST-630) (the 4th report) - Twelve-month oral repeated dose toxicity study in rats. Clin Rep 1996, 30(11): 75-105.
27. Nakamura, I., Sakagawa, T., Kawanishi, M., Ohno, R., Kimura, M., Tarumoto, Y., Isowa, K., Mitsuzono, T. Toxicity studies of (+)-(5Z,7E) - 26,26,26,27,27,27 - hexafluoro - 9,10 - secocholesta5,7,10(19)-triene-1α,3β,25-triol (ST-630) (the 5th report) - Twelve-month oral repeated dose toxicity study in beagle dogs. Clin Rep 1996, 30(11): 107-25.
28. Suzuki, H., Tarumoto, Y., Sasaki, T., Nakajima, M., Aruga, F. Mutagenicity studies of (+)-(5Z,7E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene- 1α,3β,25-triol (ST-630). Clin Rep 1996, 30(11): 127-35.
29. Katsuma, T., Tanaka, T., Ishibashi, E., Nakatsuka, M. The biological activity of ST-232, the main metabolite of falecalcitriol. Clin Rep 1996, 30(11): 307-12.
30. Ishibashi, E., Seki, H., Katsumata, T., Nakatsuka, M. Effects of falecalcitriol on osteocalcin secretion and its metabolism in human osteosarcoma cell line, MG-63. Clin Rep 1996, 30(11): 299-306.
31. Komuro, S., Kanamaru, H., Nakatsuka, I., Yoshitake, A., Ishizaki, M., Nemoto, H., Ueda, K., Ebine, H., Ninomiya, S., Esumi, Y. Disposition and metabolism of ST-630 (1): Absorption, distribution and excretion after single oral administration of 3H-ST-630 in rats. Xenobiotic Metab Dispos 1996, 11: 505-17.
32. 3H-ST-630 in rats. Xenobiotic Metab Dispos 1996, 11: 518-29.
33. 3H-ST-630 in rats. Xenobiotic Metab Dispos 1996, 11: 530-40.
34. 3H-falecalcitriol in rats, and effect of falecalcitriol on the hepatic drug-metabolizing enzyme system in rats. Clin Rep 1996, 30(11): 137-53.
35. 3H-falecalcitriol in immature rats. Clin Rep 30(11): 155-63.
36. 3H-falecalcitriol in 14 months old rats. Clin Rep 1996, 30(11): 165-74.
37. Komuro, S., Sato, M., Nakatsuka, I., Kataoka, K. Disposition and metabolism of falecalcitriol (the 8th report) - Absorption, distribution and excretion of falecalcitriol in hepatic-disordered rats. Clin Rep 1996, 30(11): 189-99.
38. 3H-falecalcitriol into the fetus and the milk after single oral administration to pregnant and lactating rats. Clin Rep 1996, 30(11): 201-20.
39. 3H-ST-232 in rats. Clin Rep 1996, 30(11): 221-30.
40. 3H-falecalcitriol in nephrectomized rats. Clin Rep 1996, 30(11): 175-87.
41. 3H-falecalcitriol in dogs. Clin Rep 1996, 30(11): 231-48.
42. 3H-falecalcitriol in dogs. Clin Rep 1996, 30(11): 249-59.
43. Akao, K., Sato, M., Komuro, S., Nakatsuka, I. Disposition and metabolism of falecalcitriol (the 13th report) - Serum protein binding of falecalcitriol and its distribution among human serum proteins. Clin Rep 1996, 30(11): 261-9.
44. 3 in cultured neonatal mouse calvaria. Res Commun Mol Pathol Pharmacol 1994, 86: 183-93.
45. 3 in the cultured neonatal mouse calvaria. Bone 1995, 16(1, Suppl.): Abst 177.
46. 3 in human serum by gas chromatography/mass spectrometry with high-resolution selected ion monitoring. Biol Mass Spectrom 1994, 23: 33-8.
47. Morii, H., Ogura, Y., Suzuki, S. et al. PTH suppressing effect of flocalcitriol in haemodialysed patients. Nephrol Dial Transplant 1993, 8(9): 1001.
48. Akiba, T., Tamura, H., Tamura, T. et al. Hexafluorocalcitriol (HF), but not alfacalcidol (ALF), suppresses secondary hyperparathyroidism in hemodialysis (HD) patients. Nephrol Dial Transplant 1996, 11(6): A40.
49. DeLuca, H.F., Ogura, Y. (Wisconsin Alumni Res. Found.). Use of 26,26,26,27,27,27-hexafluoro-1α,25-dihydroxycholecalciferol for the treatment of calcium metabolism disorders. EP 684827, WO 9418985.
50. Taisho Pharmaceutical Co., Ltd. Annual Report 1996.